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Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/ (TAL) reabsorbs approximately 30% of the total filtered
antenatal Bartter syndrome. NaCl load. Gene products mediating salt-reabsorption
Background. Hyperprostaglandin E syndrome/antenatal Bart- include the furosemide sensitive Na-K-2Cl-cotransporterter syndrome (HPS/aBS) is a congenital salt-losing tubulopathy
NKCC2 [1] and the renal potassium channel ROMKwith an induced expression of cyclooxygenase-2 (COX-2) in
[2, 3]. Both proteins are expressed in the luminal mem-the macula densa probably leading to hyperreninemia. Inhibi-
tion of stimulated prostaglandin E2 (PGE2) formation with in- brane of the TAL, including the macula densa, a special-
domethacin results in a significant improvement of clinical ized segment of the cortical TAL thought to sense lumi-
symptoms and is therefore standard therapy. Using the COX-2 nal salt concentration [4, 5]. The functional coupling ofselective inhibitor rofecoxib, we investigated the role of COX-2
the furosemide sensitive Na-K-2Cl-cotransporter and po-in the pathophysiology of HPS/aBS.
tassium channel ROMK is essential for NaCl-uptake. InMethods. Six clinically well-characterized patients with HPS/
aBS (3 girls) were enrolled into the study. Four patients had humans, defects in either one of the proteins lead to
mutations in the renal potassium channel ROMK, one patient severe salt and fluid loss [6], resembling long-term furo-
in the furosemide-sensitive cotransporter NKCC2, whereas in semide administration [7]. Saluretic polyuria is invariablyone patient no molecular abnormality could be detected. Me-
present prenatally leading to polyhydramnios and pre-dian age was 15.8 years (range: 9.1 to 19.0 years). Patients were
mature birth. Additional clinical symptoms include fever,evaluated on indomethacin treatment, 3 days after indometha-
cin withdrawal, and after 4 days of treatment with rofecoxib. osteopenia, vomiting and failure to thrive [8].
Therapeutic drug monitoring was performed. Recently, a very similar clinical phenotype was linked
Results. COX-2-selectivity of rofecoxib was confirmed in vivo
to mutations in a novel protein, designated barttin [9], andand ex vivo. Both indomethacin and rofecoxib ameliorated clin-
subsequently barttin has been shown to activate ClC-Kical symptoms, the typical laboratory findings, and significantly
suppressed PGE2 and PGE-M excretion to normal values while chloride currents up to 20-fold in the oocyte expression
it was elevated under withdrawal conditions. Rofecoxib sup- system [10, 11]. ClC-K channels are expressed along the
pressed hyperreninemia to a similar extent as indomethacin. distal nephron from the thin ascending limb to the col-Conclusion. In patients with HPS/aBS, excessive PGE2 syn-
lecting duct and are essential for chloride exit across thethesis and hyperreninemia is dependent on COX-2 activity. This
basolateral membrane. Additionally, ClC-K channels con-observation proves the stimulatory role of COX-2 on renin-
secretion in salt-depletion in humans. Clinical long-term effi- tribute to endolymph secretion in the inner ear. Loss of
cacy and potential side effects of rofecoxib need to be evaluated function of their common beta-subunit barttin, there-
in a larger cohort of HPS/aBS-patients.
fore, is invariably associated with congenital sensori-
neural deafness [12, 13].
Inherited salt-losing tubulopathies due to defectiveThe kidney is the key organ for the regulation of salt
salt reabsorption in the TAL have been termed antena-homeostasis. Different nephron segments contribute to
tal Bartter syndrome (aBS) or hyperprostaglandin E syn-salt-reabsorption. The thick ascending limb of Henle’s loop
drome (HPS). The latter designation emphasizes the piv-
otal role of prostaglandin E2 in both pathogenesis and
1 Both authors contributed equally to this work. treatment of this salt-losing tubulopathy [8–15]. Patients
affected by HPS/aBS show excessive renal and systemicKey words: COX-2, renin, rofecoxib, salt-losing tubulopathy, macula
densa, hyperreninemia, rofecoxib, prostaglandin E2. production of prostaglandin E2, thereby causing and/or
aggravating both renal and systemic disturbances (Fig. 1)Received for publication December 7, 2001
[16].and in revised form February 25, 2002
Accepted for publication March 1, 2002 Prostaglandins comprise a family of labile, bioactive
lipids mediating various physiological and pathophysio- 2002 by the International Society of Nephrology
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Fig. 1. Schematic representation of the prostaglandin cascade and its inhibition with NSAID (and COX-2 inhibitors) in relation to the tubular
salt-wasting and clinical symptoms in HPS/aBS. Abbreviations are: NSAID, non-steroidal anti-inflammatory drug; HPS/aBS, hyperprostaglandin
E syndrome/antenatal Bartter syndrome; PLs, phospholipids of the cellular membrane; PLA2, phospholipase A2; AA, arachidonic acid; COX,
cyclooxygenase; PG, prostaglandin, PGES, prostaglandin E synthase; Tx, thromboxane; ADH, antidiuretic hormone.
logical processes including renal glomerular filtration, was reported as successfully treated with the highly selec-
tive COX-2 inhibitor, rofecoxib [27].renin release, and epithelial salt and water transport [17].
Non-steroidal anti-inflammatory drugs (NSAID) such as Given both the strong evidence from experimental and
clinical studies indicating that renal induction of COX-2indomethacin block the formation of prostaglandins by
inhibiting the enzymatic activity of cyclooxygenases 1 plays an important role in the pathogenesis of HPS/aBS
as well as the gastric side effects caused by treatment withand 2 (COX-1 and COX-2) [18]. COX-1 has been pro-
posed to be a housekeeping enzyme, and its inhibition the classical, non-selective NSAID indomethacin, we used
the highly selective COX-2 inhibitor rofecoxib to inves-is associated with the well-known side effects of NSAIDs
in particular gastric ulcers and bleeding [18]. In the kid- tigate the pathophysiological role of COX-2 and the
ney, COX-1 is expressed predominantly within cells of therapeutic potential of this compound in a cohort of
the collecting duct. COX-2 is usually not expressed in HPS/aBS-patients under controlled and standardized
most tissues but can be induced by growth factors and conditions.
inflammatory cytokines [19]. In contrast to most other
tissues, the kidney is known to express COX-2 [20–22].
METHODS
In rodents salt depletion [20], renal artery stenosis [23],
Patients and study designand administration of furosemide [24] induce expression
of COX-2 in the macula densa. In contrast to control Six patients (3 girls) with HPS/aBS were enrolled into
the study. The median age was 15.8 years (range 9.1 tosubjects, patients affected by HPS/aBS also show expres-
sion of COX-2 in the macula densa [25]. In a previous 19.0 years old). Three patients had mutations in the renal
potassium channel ROMK [A103V/P110L, V315G/T332study, we have shown that nimesulide, a COX-inhibitor
with some selectivity toward COX-2 was as effective as (delAAAG), del ex1-2] and two patients in the furose-
mide sensitive cotransporter NKCC2 [R63(insT), C461R].indomethacin in patients with HPS/aBS [26]. Recently,
one patient with HPS/aBS caused by a ROMK-mutation In one patient we failed to detect any mutation in ROMK
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were measured by conventional laboratory methods. Ra-
dioimmunological standard assays were used for analysis
of plasma renin and plasma aldosterone concentration.
In our laboratory the upper normal limits for children
older one year of age are 5.2 to 33.4 pg/mL and 2.9 to
16.2 ng/dL, respectively.
Eicosanoid analysis. Urine was collected over 24 hours
under refrigerated conditions. Aliquots were stored at
80 C until analysis. For determination of prostaglandin
E2, its major metabolite prostaglandin E-M (11-hydroxy-
9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostanoic
acid), and the prostacyclin metabolite 2,3-dinor-6-keto-
prostaglandin F1 as well as thromboxane B2, and its me-Fig. 2. Blood levels of rofecoxib in patients with HPS/aBS after intro-
duction of the new treatment (days 1 to 4) and under steady state con- tabolite 11-dehydro-thromboxane B2 in the 24-hour urine
ditions (week 6). Blood for determination of the rofecoxib levels was samples and/or blood samples after ex vivo testing, gas
drawn 12 hours post-dosing. The data are given as median, and 1 and
chromatography tandem mass spectrometry was em-3 quartiles. Drug administration is symbolized by an arrow (↓).
ployed as previously described [29]. Excretion of pros-
taglandin E-M is regarded to reflect predominantly sys-
temic prostaglandin E2 production, whereas urinaryor NKCC2. This patient was subsequently tested for other
prostaglandin E2 represents renal biosynthesis [30]. Incandidate genes encoding ClC-Kb and barttin, respec-
vivo, we considered the urinary excretion of 2,3-dinor-tively, without abnormal findings. All patients were clini-
6-keto-prostaglandin F1 as an index of total body biosyn-cally characterized according to Seyberth et al [16] and
thesis of prostacyclin, which has been suggested as anhave been examined in previous studies [7, 8, 25]. All
index of COX-2–dependent prostacyclin synthesis by en-patients were on long-term indomethacin treatment (me-
dothelial cells [31]. Actual platelet COX-1–dependentdian dose 1.1 mg/kg/day; range 0.8 to 1.5 mg/kg/day).
thromboxane synthesis in vivo is reflected by urinaryThree patients were treated with additional potassium
excretion of the thromboxane metabolite 11-dehydro-chloride supplements (1.1, 1.8. and 0.5 mmol/kg/day).
thromboxane B2 [31].This medication was maintained during the entire study
Ex vivo testing of COX-2 selectivity. Monocytes andperiod. No other medication was taken by any of the
macrophages express COX-2 when induced by lipopoly-subjects.
saccharides ex vivo, producing prostaglandin E2 andLong-term indomethacin treatment (median drug level
thromboxane A2 as major products [32, 33]. Thus, inhibi-4 hours post-dosing, 778 ng/mL, range 521 to 1760 ng/mL)
tion of prostaglandin E2 formation may be used to reflectwas discontinued four days before the introduction of ro-
COX-2 inhibition ex vivo. Thromboxane A2 is the majorfecoxib to prevent drug interaction. Already 12 hours after
product of platelet COX-1, and inhibition of serumthe last dose indomethacin blood levels were below the
thromboxane B2, its hydrolysis product, reflects inhibi-range that usually suppresses induced prostaglandin syn-
tion of this isoform ex vivo. Thromboxane B2 was mea-thesis (data not shown [28]). Blood samples and cooled
sured in serum after spontaneous clotting. The details of24-hour urine collections were obtained before, and
this biochemical assays are described elsewhere [31–33].three days after withdrawal of indomethacin, and once
Blood samples for lipopolysaccharide (LPS)-induceddaily during the first four days of rofecoxib (Vioxx;
prostaglandin E2 and serum thromboxane B2 generationMerck & Co. Inc., Rahway, NJ, USA) treatment, respec-
were obtained on indomethacin, under withdrawal con-tively. During this time patients were allowed to be on
ditions and after four days of rofecoxib treatment.a self-demand dietary schedule required by the individ-
Drug levels. Serum levels of indomethacin were mea-ual loss of electrolytes and free water. Withdrawal of in-
sured using a modified high-performance liquid chroma-domethacin resulted in recurrence of the clinical picture
tography (HPLC) as described elsewhere [34]. Bloodand laboratory characteristics of this disorder (Table 2
samples for the determination of the indomethacin bloodand Fig. 3).
levels were drawn 4 and 12 hours after the last dose.The study protocol was approved by the Ethics Com-
An analytical method for the determination of rofec-mittee of the Philipps-University of Marburg. Written
oxib [4-(4-methanesulfonylphenyl)-3-phenyl-5H-furan-informed parental consent and written assent of the chil-
2-one] in human plasma has been developed, based ondren were obtained before enrollment in the study.
a slightly modified assay published by Chavez-Eng, Con-
Analytical methods stanzer and Matuszewki [35]. For this purpose rofecoxib
was extracted and recrystallized from tablets (Vioxx;Routine parameters. Urinary and serum electrolyte
concentrations, osmolality, and creatinine concentrations Merck & Co.). The internal standard [4-(4-methylsul-
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Table 1. Evaluation of COX-2 specificity during long term treatment with indomethacin and after four days of rofecoxib treatment
in relation to the indomethacin withdrawal period in patients with HPS/aBS
Indomethacin Withdrawal Rofecoxib Normal range
In vivo (N  6)
urinary 2,3-dn-6-k-PGF1 ng/h/1.73 m2 0.9a (0.0–2.1) 4.2 (2.8–7.7) 2.0a,b (1.8–2.9) 4–19
Ex vivo (N  5)
PGE2 % of withdrawal 8a (2–29) 100 15a (4–23)
TxB2 % of withdrawal 8a (6–45) 100 92 (64–295)
a P  0.05 as compared to indomethacin withdrawal
b P  0.05 as compared to indomethacin treatment
fonylphenyl)-3-(4-methylphenyl)-5H-furan-2-one] was
laboratory-synthesized using the method of Dikshit, Singh
and Kamboj [36]. For sample preparation a 96-well C18
solid-phase extraction plate with reduced sorbent (SPEC;
Ansys) was used. The analytes were eluted with acetone.
After evaporation a reconstituted solution was injected
into the HPLC-tandem mass spectrometry (PE Biosys-
tems API 3000) system. The assay was validated in the
concentration range of 5 to 500 ng/mL. The intra-assay
accuracy of this method was less than 10% bias from
the nominal concentration and the intra-assay precision
was less than 5% relative standard deviation.
Blood samples for the determination of rofecoxib
blood levels were drawn once daily during the first four
days after the introduction of rofecoxib, and again six
weeks later, 12 hours post-dosing, respectively.
Fig. 3. Urinary excretion of 11-dehydro thromboxane B2, a marker of
COX-1–dependent platelet thromboxane synthesis in vivo during long-Statistics
term treatment with indomethacin, three days after indomethacin with-
Drug levels in Figure 1 are given as median, and first drawal, and after four days of rofecoxib treatment in patients with HPS/
aBS. Normal range is below the dotted line, *P  0.05.and third quartiles. Data in the Tables are given as me-
dian and range. Wilcoxon matched-pairs signed rank test
was used for statistical analysis.
rofecoxib suppressed excretion of 2,3-dinor-6-keto-pros-
taglandin F1 less effectively than indomethacin (Ta-RESULTS
ble 1). In contrast, the stable thromboxane B2 metaboliteRofecoxib dosing
11-dehydro-thromboxane B2 was suppressed to subnor-
Rofecoxib administered once daily in a dose of 0.7 mg/ mal values by indomethacin, rose to normal values after
kg/day (equivalent to a dose of 25 mg/day in adults) discontinuation of indomethacin and did not change sig-
leads to continually increasing blood levels during the nificantly with rofecoxib (Fig. 3). These results were par-
first four days (Fig. 2). Drug levels obtained at the fourth alleled by ex vivo assays: Analysis of patients whole
day of rofecoxib-treatment and six weeks later were simi- blood in vitro revealed an almost identical suppression of
lar, indicating that a steady state was reached at the LPS induced, COX-2–dependent prostaglandin E2 syn-
fourth day. To obtain sufficient suppression of stimulated thesis by both indomethacin and rofecoxib compared to
PGE2 synthesis blood levels of more than 100 ng/mL withdrawal conditions (Table 1). However, in contrast
were needed when measured 12 hours post-dosing. to indomethacin treatment rofecoxib did not significantly
suppress ex vivo thromboxane synthesis (Table 1).
COX-2 selectivity of rofecoxib
Effects of rofecoxib treatmentTo verify specific inhibition by this medication, COX-2
selectivity was analyzed both in vivo and in vitro. The Treatment with rofecoxib suppressed prostaglandin
urinary excretion rate of 2,3-dinor-6-keto-prostaglandin E2 (Fig. 4A) and prostaglandin E-M (median 294 ng/h/
F1 reflecting systemic prostacyclin synthesis in vivo, was 1.73 m2, range 115 to 660 ng/h/1.73 m2, normal range 62
significantly lower with both indomethacin and rofecoxib to 482 ng/h/1.73 m2) to normal values. In contrast to
the equivalent suppression of prostaglandin E2 synthesis,compared with the washout period (Table 1).] However,
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Fig. 4. Urinary prostaglandin E2 excretion (A) and plasma renin concentration (B) during long term treatment with indomethacin, three days
after indomethacin withdrawal, and after four days of rofecoxib treatment in patients with HPS/aBS. Normal range is below the dotted line, *P 
0.05.
Table 2. Clinical and biochemical changes (effects) of indomethacin and rofecoxib in patients with HPS/aBS (N  6) in contrast to the
withdrawal period
Indomethacin Withdrawal Rofecoxib Normal range
Serum potassium
mmol/L 3.4 (3.1–4.3) 3.4 (2.9–3.7) 3.6 (3.3–4.3) 3.6–4.8
Serum pH 7.39a (7.37–7.40) 7.42 (7.40–7.44) 7.39a (7.36–7.42) 7.35–7.45
Serum chloride
mmol/L 104 (101–107) 101 (99–104) 104 (102–106) 97–106
Aldosterone ng/dL 18.5a (4.0–51.2) 41.6 (15.8–144.0) 8.5a (5.6–28.1) 2.9–16.2
Diuresis mL/kg*h 2.0a (1.2–6.2) 3.1 (1.5–8.3) 1.9a (1.1–5.9) 1.00.2b
FE potassium % 16.0 (5.5-51.0) 25.7 (14.0–38.2) 16.6a (9.8–26.8) 15
Chloride excretion
mmol/kg/day 2.1 (1.5–8.1) 4.0 (1.5–7.1) 3.0 (1.2–7.9) 2.30.3b
Sodium excretion
mmol/kg/day 1.8 (1.5–7.7) 3.7 (1.5–6.0) 2.7 (1.1–6.7) 1.90.3b
Calcium excretion
mg/kg/day 5.6a (2.4–22.2) 10.4 (3.7–28.6) 5.3a (2.3–20.3) 4
Creatinine clearance
mL/min/1.73 m2 87a (74–95) 106 (86–124) 82 (65–122) 80–160
Urinary osmolality
mOsmL/kg 284 (163–377) 272 (132–377) 279 (200–417) 300
Data are given as median and range.
a P  0.05 as compared to withdrawal conditions
b From Ko¨ckerling et al, 1996 [7]
rofecoxib suppressed hyperreninemia more effectively (Table 2). No changes in blood pressure were observed
than indomethacin (P  0.05; Fig. 4B). However, the in patients under rofecoxib treatment (data not shown).
amelioration of the secondary hyperaldosteronism was
not different between the two treatment regimens (Ta-
DISCUSSIONble 2). Rofecoxib treatment improved hypochloremic
This study used the COX-2 selective inhibitor, rofec-metabolic alkalosis, polyuria, hypercalciuria, and the frac-
oxib, to treat patients with HPS/aBS. This treatmenttional excretion of potassium to a similar extent as indo-
was well tolerated by the patients, who had no adversemethacin (Table 2). Similarly, both indomethacin and
reactions. Drug levels obtained at the fourth day of rofec-rofecoxib treatment reduced creatinine clearance by
oxib treatment and six weeks later were similar, indicat-15% compared to the washout phase, while the isosthen-
uria was not influenced significantly by either treatment ing that a steady state was reached at the fourth day.
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Fig. 5. Pathophysiologic relationships of defect tubular salt reabsorption in the medullary thick ascending limb of Henle’s loop (mTAL). The
consequent high tubular salt concentration in the cortical tick ascending limb (cTAL), defective sensing of tubular salt concentration in the macula
densa and subsequent stimulation of COX-2 expression by MAP-kinase p38 leading to exocytosis of renin by juxtaglomerular granular cells
probably via the stimulating adenylate cyclase coupling prostaglandin E receptor subtype EP4 or EP2 is shown. In addition, the possible interactions
of sympathetic nerve activity and renal perfusion pressure are depicted [48]. Abbreviations are: 1, 1-adrenergic receptor; cAMP, cyclic adenosine
monophosphate; CCD, cortical collecting duct; DT, distal tubule; IMCD, inner medullary collecting duct; MD, macula densa; PT, proximal tubule;
MIC, medullary interstitial cell, percentage of physiologically reabsorbed NaCl.
The steady-state blood levels reached with a compara- ity [31], was significantly more suppressed by indometha-
cin than by rofecoxib. This finding indicates, that in ourtively high dose of rofecoxib (0.7 mg/kg/day) were only
half as high as reported from healthy adult volunteers patients prostacyclin-synthesis is not strictly COX-2–
dependent. Ex vivo, LPS-induced COX-2–dependenttreated with a dose of 25 mg once daily [37]. The differ-
ences in drug levels are probably explained by the inter- prostaglandin E2 formation was fully inhibited by rofec-
oxib. Collectively, these data demonstrate both efficientassay variability (fluorescence vs. tandem mass spectro-
metric detection) and/or by the higher metabolic rate in and highly selective inhibition of COX-2 with rofecoxib.
Compared to our previous study with nimesulide, thechildren and adolescence compared to adults.
The selectivity of our rofecoxib treatment was rigor- higher selectivity of rofecoxib is indicated by a higher sup-
pression of renin secretion and a lack of the inhibitory ef-ously assessed both in vivo and ex vivo to assure that the
therapeutic effects of rofecoxib indeed were mediated by fect on the excretion of 11-dehydro-thromboxane B2 [26].
Nevertheless, rofecoxib ameliorated the characteristicinhibition of COX-2. In both approaches (that is, in vivo
and ex vivo) rofecoxib, unlike indomethacin, did not af- features of the salt-losing tubulopathy, that is, hyperpros-
taglandinuria, secondary hyperaldosteronism, hypochlo-fect COX-1–dependent platelet thromboxane synthesis.
Endothelial prostacyclin synthesis, which has been pro- remic/hypokalemic metabolic alkalosis, polyuria, renal
sodium and potassium wasting, and hypercalciuria to aposed to indicate constitutive endothelial COX-2 activ-
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similar extent as indomethacin. Improvement of the din E2 receptors subtypes EP2 and EP4. The latter has
renal disturbances with selective inhibition of COX-2 been shown to be abundantly expressed in glomeruli,
fully supports the notion that induction of COX-2 plays although it has not been specifically localized to juxta-
a critical role in the pathogenesis of HPS/aBS and is glomerular epitheloid cells (Fig. 5) [46, 47].
thus the main therapeutic target. Our data suggest that Taken together, by selective inhibition of COX-2 we
COX-2 selective inhibition might be advantageous for have shown that in patients with HPS/aBS the systemic
patients with HPS/aBS since the most relevant side ef- alterations downstream of primary tubular defect (that
fects of long-term indomethacin administration, namely is, ROMK and NKCC2 mutations) are primarily depen-
gastrointestinal complications and a prolonged bleed- dent on COX-2 activity. The positive results of this study,
ing time resulting from inhibition of COX-1 activity, in addition the effectiveness and safety of this new treat-
probably will be a minor problem with rofecoxib. How- ment, need to be confirmed in a larger number of patients
ever, since renal development is critically dependent on with HPS/aBS.
COX-2 activity, this drug should be used with great cau-
tion in patients with HPS/aBS pre- and postnatally (criti- ACKNOWLEDGMENTS
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